iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Aurobindo Pharma: Strong pipeline of growth levers across spaces

3 Apr 2024 , 11:21 AM

Post analysts of IIFL Securities' recent meeting with Aurobindo’s mgmt, they upgraded their rating on the stock from ADD to BUY, given Aurobindo has several growth levers over near-to-medium term including the recent commercialisation of the Pen-G API plant and the Vizag injectables plant, expected commissioning of the China plant in H1FY25 for supplies to EU markets, US base business growth (exEugia) of 6-8% to be driven by 35-40 new launches pa (Deflazacort will be a limited-competition launch in Q1FY25), Eugia’s near-term growth to be driven by scale-up in Revlimid and launches from plants other than Unit-3, and potential launch of biosimilars from FY26 and biologics CDMO contract with MSD from FY28. Analysts of IIFL Securities upgrade FY25/26 EPS by 2-3% to account for higher margins led by the Pen-G project and their TP of Rs1,330 (19x 2YF EPS) implies 21% upside. Although analysts of IIFL Securities base case assume an OAI/WL on Eugia Unit-3, an import alert will lead to 5-7% downgrade to their EBITDA estimates in the worst-case scenario.

Eugia Unit-3 CAPA response has been submitted to USFDA and Aurobindo has restarted existing product distribution post the consultation with external cGMP consultants. While non-aseptic production lines have already restarted, Aurobindo remains on track to restart all the 8 aseptic lines by mid-Apr’24. Assuming USD20m revenue impact in Q4FY24, analysts of IIFL Securities believe Eugia will clock global sales of USD520-530m in FY24. Base biz volume growth, ramp-up in Revlimid sales from USD45m in FY24 to USD90m in FY25, along with USD15-20m of new product sales (largely from Eugia Unit-1), will help Eugia clock USD600-620m sales in FY25.

Commercial production of Pen-G has started:

With Aurobindo’s external supplies expected to be 50-60% of its overall Pen-G capacity of 15K TPA, analysts of IIFL Securities expect Aurobindo’s external Pen-G sales to be USD90/165m in FY25/26, assuming price of USD22/kg & yield optimisation by Sep’24. With 25% core Ebitda margins and incentives of Rs2.4bn p.a., analysts of IIFL Securities expect Pen-G project to add ~7-8% to Aurobindo’s FY25/26 Ebitda.

Aurobindo’s base US biz (ex-Eugia) will likely grow at 6-8% Cagr, driven by 35-40 new launches p.a. and volume growth of 5%, assuming mid-single-digit price erosion. As per industry channel checks, US price erosion is expected to remain stable at-least till mid-CY24. Analysts of IIFL Securities believe Deflazacort launch in Q1FY25 (mkt size of USD260m) could contribute USD50m sales pa, given Aurobindo will be the sole generic in the market.

Related Tags

  • Aurobinda Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp